Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis
Purpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an i...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2452987 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832583977970434048 |
|---|---|
| author | C. Grote F. Zirkenbach J. N. Wagner M. Augustin |
| author_facet | C. Grote F. Zirkenbach J. N. Wagner M. Augustin |
| author_sort | C. Grote |
| collection | DOAJ |
| description | Purpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis. At first, dupilumab was continued alongside doxycycline, metronidazole gel and ivermectin cream.Results Following a worsening of her skin condition, dupilumab was discontinued. Lebrikizumab was introduced, leading to significant regression of the lesions.Conclusions This case highlights a rare paradoxical skin reaction to dupilumab, potentially linked to the blockade of IL-4Rα, which may shift the immune response towards a Th1/Th17 phenotype. The findings suggest that alternative therapies, such as IL-13 inhibitors, should be considered when cutaneous side effects arise during dupilumab treatment. |
| format | Article |
| id | doaj-art-5d698ef14c7c419fbe3ffce69b9b5123 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-5d698ef14c7c419fbe3ffce69b9b51232025-01-28T01:18:17ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2025.2452987Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitisC. Grote0F. Zirkenbach1J. N. Wagner2M. Augustin3Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, GermanyInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, GermanyInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, GermanyInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, GermanyPurpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis. At first, dupilumab was continued alongside doxycycline, metronidazole gel and ivermectin cream.Results Following a worsening of her skin condition, dupilumab was discontinued. Lebrikizumab was introduced, leading to significant regression of the lesions.Conclusions This case highlights a rare paradoxical skin reaction to dupilumab, potentially linked to the blockade of IL-4Rα, which may shift the immune response towards a Th1/Th17 phenotype. The findings suggest that alternative therapies, such as IL-13 inhibitors, should be considered when cutaneous side effects arise during dupilumab treatment.https://www.tandfonline.com/doi/10.1080/09546634.2025.2452987Dupilumabrosaceaskin side effectsIL-4RαIl-13 |
| spellingShingle | C. Grote F. Zirkenbach J. N. Wagner M. Augustin Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis Journal of Dermatological Treatment Dupilumab rosacea skin side effects IL-4Rα Il-13 |
| title | Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis |
| title_full | Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis |
| title_fullStr | Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis |
| title_full_unstemmed | Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis |
| title_short | Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis |
| title_sort | rosacea like skin reaction under treatment with dupilumab for atopic dermatitis |
| topic | Dupilumab rosacea skin side effects IL-4Rα Il-13 |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2025.2452987 |
| work_keys_str_mv | AT cgrote rosacealikeskinreactionundertreatmentwithdupilumabforatopicdermatitis AT fzirkenbach rosacealikeskinreactionundertreatmentwithdupilumabforatopicdermatitis AT jnwagner rosacealikeskinreactionundertreatmentwithdupilumabforatopicdermatitis AT maugustin rosacealikeskinreactionundertreatmentwithdupilumabforatopicdermatitis |